Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California. As of February 5, 2025, Avid Bioservices, Inc. was taken private.
Private Equity Pivot | Explore Avid Bioservices' transition to private ownership, valued at $1.1 billion, and its potential impact on the company's growth trajectory and market position |
Gene Therapy Frontie | Delve into Avid's expanding capabilities in gene therapy manufacturing, a promising growth area that could reshape the company's future in biopharmaceuticals |
Financial Crossroads | Uncover the complexities of Avid's financial performance, balancing revenue growth with profitability challenges and a FY2025 revenue guidance of $160-168 million |
Market Valuation | Analyst price targets range from $8 to $12.50, reflecting varied perspectives on Avid's potential in the competitive CDMO landscape |